GENE ONLINE|News &
Opinion
Blog

Ovarian Cancer
AbbVie Invests $10.1 Billion in ImmunoGen, Targeting the Ovarian Cancer Landscape
2023-12-05
Deceptive Health Advice on TikTok Raises Concerns About Gynecologic Cancer Misinformation
2023-09-20
Deep Into Bankruptcy Proceedings, Clovis Sells Cancer Med Rubraca
2023-04-10
Johnson & Johnson to Pay $8.9 Billion Over 25 Years to Settle Talcum Powder Lawsuits
2023-04-06
J&J’s Market Value Plummets by $17 Billion After Appeals Court Denies Bankruptcy Escape
2023-01-31
ImmunoGen Wins FDA Accelerated Approval For Ovarian Cancer Drug
2022-11-16
EMA Recommends Restriction on Rubraca
2022-07-25
Lynparza Bags Multiple Approvals in Japan
2021-01-05
FMI’s Liquid Biopsy Test Adds 3 Companion Diagnostic Indications for Advanced Ovarian, Breast and Lung Cancers
2020-10-30
Korean Biotech, AbClon Enters Trials with New CAR-T Molecule against Ovarian Cancer
2020-04-23
Lynparza Meets Primary Endpoint in Phase III PROfound Trial
2019-08-16
First PARP inhibitor approved for 1L maintenance therapy of BRCAm advanced ovarian cancer
2018-12-28
LATEST
Pharmaceutical Giants Expand Research and Manufacturing Capabilities, Fueling 2024 Innovation and Growth
2024-03-01
An Interview with the Inventor of HPV Vaccine, Ian Frazer, Building a Firewall for Public Health
2024-02-29
Taiwan’s Drug Price Adjustments: Balancing Cost and Availability
2024-02-28
Neomorph Links Together With Novo Nordisk in a $1.46 Billion Molecular Glue Partnership Deal
2024-02-27
Breakthrough Study Shows Anti-IgE Antibody Safeguards Children with Multiple Food Allergies
2024-02-27
Cortisol: New Discoveries on its Impact Across Health, Culture, and Evolution
2024-02-26
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
2024-02-23
EVENT
Scroll to Top